Results 11 to 20 of about 6,910 (195)

Clozapine-Associated Pulmonary Embolism: Continuation of Clozapine Therapy With Concurrent Anticoagulation. [PDF]

Case Rep Psychiatry
Clozapine, a gold standard for treatment‐resistant schizophrenia, is associated with a range of adverse effects, including the rare but serious risk of pulmonary embolism (PE). The management of such complications, particularly in the absence of clear guidelines for preventive anticoagulation, poses significant challenges.
Jahangir MR, Heerema C, Biedermann J, Dieleman S, Grootendorst-van Mil NH.   +4 more
europepmc   +2 more sources

Quality of vitamin K antagonist treatment during the last year of life. [PDF]

Hemasphere
Abstract Limited data exist on the quality of anticoagulation in patients approaching the end of life. This study evaluated vitamin K antagonist (VKA) anticoagulation control during the last year of life, using nationwide data from Statistics Netherlands, linked to anticoagulation clinics' data and the Netherlands Cancer Registry. We included prevalent
Visser C, Kempers EK, Goedgebuur J, Abbel D, Aldridge SJ, Edwards A, Edwards M, Geersing GJ, Ording AG, van de Leur SJCM, Lifford KJ, Mahé I, Mooijaart SP, Nierman MC, Portielje JEA, Søgaard M, Szmit S, Wiersma NM, Noble SIR, Klok FA, Chen Q, Cannegieter SC, Geijteman ECT, Kruip MJHA, SERENITY Consortium.   +24 more
europepmc   +2 more sources

Determining Drug Exposure Based on Medication Dispensing Data: A Validation Study of Vitamin K Antagonist Treatment Episodes Against INR Records. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Background In pharmaco‐epidemiological studies using vitamin K antagonist (VKA) exposure, constructing treatment episodes based on dispensed prescriptions is challenging, particularly due to the large variability in therapeutic dose.
Kempers EK, Visser C, Goedegebuur J, Chen Q, Søgaard M, Ording AG, van den Dries C, Abbel D, Aldridge SJ, Lifford KJ, Portielje JEA, Nierman MC, Boetes-Draisma A, van de Leur SJCM, Klok FA, Geijteman ECT, Kruip MJHA, Cannegieter SC.   +17 more
europepmc   +2 more sources

A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. [PDF]

PLoS ONE, 2010
The identification of CYP2C9 and VKORC1 genes has strongly stimulated the research on pharmacogenetics of coumarins in the last decade. We assessed the combined influence of CYP2C9 *2 and *3, and VKORC1 c.-1639G>A, 497C>G, and 1173C>T variants, on ...
Zoraida Verde, Jonatan R Ruiz, Catalina Santiago, Beatriz Valle, Fernando Bandrés, Elpidio Calvo, Alejandro Lucía, Félix Gómez Gallego   +7 more
doaj   +1 more source

SAFETY OF TEETH EXTRACTIONS IN PATIENTS ON ACENOCOUMAROL THERAPY [PDF]

Journal of IMAB, 2020
Introduction: Studies evaluating bleeding risk in anticoagulated patients undergoing dental surgical procedures have been conducted for more than 50 years and are still ongoing.
Atanaska Dinkova, Hristo Daskalov
doaj   +1 more source

Improvement in the regulation of the vitamin K antagonist acenocoumarol after a standard initial dose regimen: prospective validation of a prescription model [PDF]

, 2008
Background In a retrospective study we have developed a model which determines the dose of acenocoumarol based on the age of the patient and on the first INR obtained after a standard initial loading dose.
Augueste Sturk, Barbara A. Hutten, Johanna H. H. Van Geest-Daalderop, Marcel Levi, Nathalie C. V. Péquériaux   +4 more
core   +9 more sources

Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol [PDF]

, 2002
The 2C9*3 and 2C9*2 polymorphisms of cytochrome P-450 CYP2C9 are associated with hypersensitivity to warfarin and bleeding. The effect of these polymorphisms on sensitivity to acenocoumarol is unknown.
Alberca, I. (Ignacio), Hermida, J. (José), Lopez, M.L. (María Luz), Molina, E. (Eva), Montes, R. (Ramón), Rocha, E. (Eduardo), Zarza, J. (José)   +6 more
core   +1 more source

Development of a Fluorescent Microfluidic Device Based on Antibody Microarray Read-Out for Therapeutic Drug Monitoring of Acenocoumarol

Frontiers in Bioengineering and Biotechnology, 2022
The development of a proof-of-concept point-of-care (PoC) device for the determination of oral anticoagulants determination is presented. Acenocoumarol (ACL) is prescribed to prevent certain cardiovascular diseases related to the prevention of deep vein ...
J.-Pablo Salvador, J.-Pablo Salvador, Thomas Brettschneider, Christian Dorrer, M.-Pilar Marco, M.-Pilar Marco   +5 more
doaj   +1 more source

Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort [PDF]

, 2017
Essentials: The knowledge of quality and safety of acenocoumarol and phenprocoumon use in children is limited. We used data from a multicenter retrospective follow-up study in children in the Netherlands.
Appel, I.M. (Inge), Bierings, M. (Marc), De Boer, A. (Anthonius), Maagdenberg, H. (H.), Maitland-van der Zee, A-H. (Anke-Hilse), Meer, F.J.M. (Felix) van der, Ommen, C.H. (Heleen) van, Tamminga, R.   +7 more
core   +1 more source

OPINION SURVEY OF THE CARDIOLOGISTS IN BULGARIA REGARDING THERAPY WITH ACETYLSALICYLIC ACID, CLOPIDOGREL AND ACENOCOUMAROL IN PATIENTS UNDERGOING DENTAL EXTRACTIONS [PDF]

Journal of IMAB, 2017
Purpose: Cardiovascular diseases are the leading cause of mortality and disability worldwide. Major role in the treatment and prophylaxis of these diseases and their complications has antiplatelet and anticoagulation therapy. Routine practice in the past
Atanaska Dinkova, Dimitar Atanasov, Lyudmila Vladimirova-Kitova   +2 more
doaj   +1 more source